

Synthesis and biological evaluation of NAS-21 and NAS-91 analogues as potential inhibitors of the mycobacterial FAS-II dehydratase enzyme Rv0636

Veemal Bhowruth, Alistair K. Brown and Gurdyal S. Besra

University of Birmingham, School of Biosciences, Edgbaston, Birmingham B15 2TT, UK

Correspondence

Gurdyal S. Besra
g.besra@bham.ac.uk

The identification of potential new anti-tubercular chemotherapeutics is paramount due to the recent emergence of extensively drug-resistant strains of *Mycobacterium tuberculosis* (XDR-TB). Libraries of NAS-21 and NAS-91 analogues were synthesized and evaluated for their whole-cell activity against *Mycobacterium bovis* BCG. NAS-21 analogues **1** and **2** demonstrated enhanced whole-cell activity in comparison to the parental compound, and an *M. bovis* BCG strain overexpressing the dehydratase enzyme Rv0636 was resistant to these analogues. NAS-91 analogues with *ortho*-modifications gave enhanced whole-cell activity. However, extension with biphenyl modifications compromised the whole-cell activities of both NAS-21 and NAS-91 analogues. Interestingly, both libraries demonstrated *in vitro* activity against fatty acid synthase II (FAS-II) but not FAS-I in cell-free extracts. In *in vitro* assays of FAS-II inhibition, NAS-21 analogues **4** and **5** had IC₅₀ values of 28 and 19 µg ml⁻¹, respectively, for the control *M. bovis* strain, and the *M. bovis* BCG strain overexpressing Rv0636 showed a marked increase in resistance. In contrast, NAS-91 analogues demonstrated moderate *in vitro* activity, although increased resistance was again observed in FAS-II activity assays with the Rv0636-overexpressing strain. Fatty acid methyl ester (FAME) and mycolic acid methyl ester (MAME) analysis of *M. bovis* BCG and the Rv0636-overexpressing strain revealed that the effect of the drug was relieved in the overexpressing strain, further implicating and potentially identifying Rv0636 as the target for these known FabZ dehydratase inhibitors. This study has identified candidates for further development as drug therapeutics against the mycobacterial FAS-II dehydratase enzyme.

Received 9 February 2008

Revised 18 April 2008

Accepted 21 April 2008

INTRODUCTION

The emergence of multi-drug resistant *Mycobacterium tuberculosis* (MDR-TB) (Kaye & Frieden, 1996) and the more recent identification of extensively drug-resistant *M. tuberculosis* (XDR-TB) (CDC, 2006) has highlighted the need for new TB drugs. Mycolic acids (C₆₀–C₉₀) are vital cell wall components of *M. tuberculosis* which form a lipid-rich permeability barrier. Currently, isoniazid represents the mainstay for chemotherapy against TB; it is known to target mycolic acid biosynthesis (Banerjee *et al.*, 1994). Mycolic acid biosynthesis involves both fatty acid synthase-I (FAS-I) and fatty acid synthase-II (FAS-II), with FAS-II being uniquely found in bacteria, plants and apicomplexan parasites, such as *Plasmodium* (Takayama *et al.*, 2005; Waller *et al.*, 2003). *M. tuberculosis* FAS-I catalyses *de novo* synthesis of intermediate-length (principally C₁₆ and C₂₄)

fatty acids. FAS-II, however, is incapable of *de novo* fatty acid synthesis and accepts short-chain (C₁₆) acyl-CoA primers from FAS-I via a condensation reaction carried out by β -ketoacyl-ACP synthase III (*mtFabH*) (Brown *et al.*, 2005; Choi *et al.*, 2000). This newly formed β -ketoacyl-ACP is reduced by a β -ketoacyl-ACP reductase (MabA) (Banerjee *et al.*, 1998) to form a β -hydroxyl-acyl-ACP intermediate. The product is then dehydrated by β -hydroxyacyl-ACP dehydratase (designated FabA and FabZ in *Escherichia coli*), followed by further reduction with the enoyl-ACP reductase, InhA, to complete the FAS-II cycle (Banerjee *et al.*, 1994; Kikuchi & Kusaka, 1984). Subsequent FAS-II cycles are initiated by the acyl-ACP-primed β -ketoacyl-ACP synthases KasA and KasB, respectively (Kremer *et al.*, 2000; Mdluli *et al.*, 1998; Schaeffer *et al.*, 2001), to afford a meromycolic acid (C₅₆), which is then condensed with a C₂₆ fatty acid (Gande *et al.*, 2004; Portevin *et al.*, 2005; Takayama *et al.*, 2005). The oxomycolic acid intermediate is then reduced to form the mature mycolic acid (Lea-Smith *et al.*, 2007).

Abbreviations: ACP, acyl carrier protein; FAMES/MAMES, fatty/mycolic acid methyl esters; FAS, fatty acid synthase; MeOH, methanol; MTBE, methyl *tert*-butyl ether; NaOMe, sodium methoxide; TB, tuberculosis.

The dehydratase enzymes FabZ and FabA have been extensively studied in both *E. coli* and *Plasmodium falciparum* (Leesong *et al.*, 1996; Sharma *et al.*, 2003). Both FabZ and FabA catalyse the dehydration of the β -hydroxyacyl-ACP to a *trans*-2-enoyl ACP in the third step of fatty acid elongation. In addition to performing the dehydration step, FabA has the ability to isomerize *trans*-2- to *cis*-3-decanoyl-ACP (Fig. 1), as an essential step in the formation of unsaturated fatty acids in *E. coli* (Kass & Bloch, 1967; Kass *et al.*, 1967). The pivotal role played by FabZ and FabA makes them good potential drug targets against *M. tuberculosis*. The identification of the key FAS-II dehydration step in mycobacteria has remained an enigma until very recently (Sacco *et al.*, 2007).

In an attempt to establish whether Rv0636 represented the potential dehydratase candidate, overexpression studies were performed in *M. bovis* BCG against a series of flavonoid inhibitors known to target FabZ (Brown *et al.*, 2007b). Of the five flavonoids tested, four were found to be active against *M. bovis* BCG with MICs ranging from 150 to 220 μ M, the most potent being butein. The activity of the flavonoids against the hypothesized gene product Rv0636 indicated that the overexpression in *M. bovis* BCG conferred resistance to butein and isoliquirtigenin (Brown *et al.*, 2007b). The data suggested that the flavonoids are inhibitors of mycobacterial FAS-II and in particular Rv0636, reiterating the potential candidacy of this gene product as the dehydratase enzyme of the FAS-II in *M. tuberculosis*.

Sacco *et al.* (2007) had independently demonstrated that the Rv0635–Rv0637 operon encoded dehydratase activity. The recombinant expression of the candidate protein cluster, Rv0635–Rv0636–Rv0637, led to the formation of two heterodimers, Rv0635–Rv0636 (HadAB) and Rv0636–Rv0637 (HadBC), which were shown to also occur in *Mycobacterium smegmatis* (Sacco *et al.*, 2007). Both heterodimers exhibited the enzymic properties expected for mycobacterial FAS-II dehydratases, including a marked specificity for both long-chain ($>C_{12}$) and ACP-linked substrates (Sacco *et al.*, 2007). Furthermore, the authors of this study were able to show the function of Rv0636 or HadAB/ HadBC as a β -hydroxyacyl dehydratase when coupled with MabA and InhA enzymes from *M. tuberculosis* FAS-II.

Further research into potential dehydratase inhibitors has yielded the identification of NAS-21 and NAS-91, which have been shown to target β -hydroxyacyl-ACP dehydratase FabZ of *P. falciparum* (Sharma *et al.*, 2003). A decrease in

the rate of enzyme activity was observed in the presence of both NAS-21 and NAS-91 using spectrometric and HPLC methods. The authors of that study also showed that the incorporation of [2- 14 C]malonyl-CoA into fatty acids in cell-free extracts of *P. falciparum* was inhibited to different extents by NAS-21 and NAS-91. The incorporation of [1, 2- 14 C]acetic acid into fatty acids was reduced by 26 and 46 %, respectively, in the presence of 10 μ M NAS-21 and NAS-91. To investigate the potential anti-mycobacterial therapeutic activity of NAS-21 and NAS-91, we synthesized a library of these FabZ inhibitors. Using a similar strategy to that previously presented (Brown *et al.*, 2007b), we evaluated the analogues for their whole-cell activity against *M. bovis* BCG and an Rv0636-overexpressing *M. bovis* BCG strain, and their *in vitro* activity against FAS-I and FAS-II in cell-free assays using *M. smegmatis* extracts.

METHODS

Synthesis of NAS-21 analogues. A series of NAS-21 analogues were developed using a previously described method (Sharma *et al.*, 2003) (Scheme 1). In brief, acetophenone derivatives were condensed with ethyl trifluoroacetate in the presence of 25 % NaOMe (in MeOH) and methyl-*tert*-butyl ether. Diversity was introduced into these reactions using a variety of commercially available acetophenone derivatives, yielding analogues 1–6 (Table 1). Biphenyl analogues 7–9 were developed via Suzuki coupling of 4-iodoacetophenone with aryl boronic acid derivatives. The product was then subjected to treatment with ethyl trifluoroacetate, 25 % NaOMe in MeOH and MTBE (Scheme 1) to yield the desired analogues 7–9. An example of the Suzuki coupling reaction for analogue 7 is as follows. 4-Iodoacetophenone (100 mg, 0.292 mmol, 1 eq.), ethylene glycol dimethyl ether (3 ml), aqueous Na₂CO₃ (0.5 ml, 1 M) and 4-fluorophenylboronic acid (48.97 mg, 0.37 mmol, 1.2 eq.) in a round-bottom flask was degassed for 10 min. Bis(triphenylphosphine) palladium chloride (8 mg, 7×10^{-3} , 5 mol%) was then added and the mixture was heated under reflux for 6 h. The mixture was partitioned between water (10 ml) and ethyl acetate (10 ml) and separated. The aqueous layer was acidified to pH 2 with dilute hydrochloric acid (2 M) and the product was extracted with ethyl acetate (2 \times 10 ml). The organic layers were combined, washed with saturated brine (3 \times 10 ml), dried and reduced to give the crude product. Purification was achieved via two separate silica gel columns. The first column used chloroform in methanol (95:5, v/v) as eluant and the second column used ethyl acetate in petroleum ether (35:65). The title analogue gave a white solid in 78 % yield (62 mg). ¹H NMR (CDCl₃, 300 MHz) δ_{H} : 2.60 (s, 3H, CH₃, H-14), 7.05 (d, 2H, H-5, H-7, *J*=8.5 Hz), 7.50 (d, 2H, H-4, H-8, *J*=8.5 Hz), 7.60 (d, 2H, H-3, H-9, *J*=8.0 Hz), 7.95 (d, 2H, H-2, H-10, *J*=8.0 Hz). ¹³C NMR (CDCl₃, 75 MHz) δ_{C} : 23.8 (C-14), 116.0, 127.4, 129.8 (C-2, 3, 4, 5, 7, 8, 9, 10), 132.0 (C-12), 136.7 (C-1), 142.0 (C-11), 168.4 (C-6), 195.6 (C-13); *m/z* (EI) 214.2 [M⁺] (100 %); HRMS calculated for C₁₄H₁₁FO [M⁺] 214.2319 found 214.2327.





Fig. 1. Dehydration and isomerization of 3-hydroxydecanoyl-ACP by *E. coli* FabA.



Scheme 1. Method for production of NAS-21 analogues.

Synthesis of NAS-91 analogues. NAS-91 was synthesized as described by Sharma *et al.* (2003). The reaction involves the coupling of 2-bromo-4-chlorophenol with 5-chloro-8-hydroxyquinolone, using caesium carbonate, copper (I) chloride (0.5 eq.) and *N*-methylpyrrolidinone as the solvent (Scheme 2) (Ullmann & Sponagel, 1905). An alternative method was developed to synthesize the remaining NAS-91 analogues in Table 2. A linker arm was introduced into 5-chloro-8-hydroxyquinolone by reacting it with benzyl bromide derivatives under basic conditions (Scheme 3). Diversity was introduced into this library by utilizing a variety of commercially available benzyl bromide derivatives. This method was employed to generate a library of seven novel NAS-91 analogues (**10–16**) (Table 2), which contain a methylene linker arm connected to the oxygen of 5-chloro-8-hydroxyquinolone. As an example, analogue **10** was synthesized as follows. 5-Chloro-8-hydroxyquinolone (500 mg, 2.78 mmol, 1 eq.) was dissolved in 5 ml dimethylformamide. To this was added caesium carbonate (452 mg, 1.39 mmol, 0.5 eq.). After 20 min of mixing at room temperature, benzyl bromide (0.37 ml, 3.06 mmol, 1.1 eq.) was added dropwise and the reaction was stirred at room temperature overnight. The reaction mixture was quenched with water. The organic layer was extracted with ethyl acetate, washed with water and brine, dried and reduced *in vacuo* to yield the crude product. The title analogue **10** was recrystallized to give a white solid in 85 % yield (635 mg). $^1\text{H NMR}$ (CDCl_3 , 300 MHz) δ_{H} : 5.35 (s, 2H, CH_2 , H-11), 6.85 (d, 1H, H-7, $J=8.44$ Hz), 7.15–7.45 (m, 4H, H-12, H-14, H-15, H-16), 7.48–7.50 (m, 3H, H-3, H-6, H-13), 8.40 (d, 1H, H-4, $J=8.54$ Hz), 8.90 (d, 1H, H-2, $J=4.17$ Hz). $^{13}\text{C NMR}$ (CDCl_3 , 75 MHz) δ_{C} : 68.9 (C-11), 107.8 (C-7), 120.4 (C-3), 124.3 (C-5), 124.5 (C-6), 125.2 (C-13, C-17), 126.1, 126.8, 127.2 (C-15, C-16, C-17), 130.8 (C-4), 134.5 (C-12), 138.1 (C-9), 147.8 (C-2), 153.2 (C-8); 3019.6m, 1638.3m, 1215.6s; m/z (EI) 369.06 [M^+] (30%), 91.00 [$\text{C}_6\text{H}_6\text{CH}_2^+$] (100%); HRMS calculated for $\text{C}_{16}\text{H}_{12}\text{ClNO}$ [M^+] 269.0607 found 269.0603.

Bacterial strains, growth conditions and MIC_{99} determination.

All reagents were of assay grade and purchased from Sigma-Aldrich. Overexpression of pVV16-Rv0636 (Brown *et al.*, 2007b) was conducted in *M. bovis* BCG on Middlebrook 7H10 agar supplemented with oleic-albumin-dextrose-catalase (OADC) enrichment (BD and Company) and containing 25 μg kanamycin ml^{-1} and 50 μg hygromycin ml^{-1} (Kremer *et al.*, 1995). Liquid cultures of *M. bovis* BCG were grown at 37 °C in Sauton's medium containing 25 μg kanamycin ml^{-1} and 50 μg hygromycin ml^{-1} . MIC_{99} values of NAS analogues against *M. bovis* BCG/pVV16 and *M. bovis* BCG/pVV16-Rv0636 were determined by Alamar Blue as described previously using the manufacturer's protocol (Celltiter-Blue; Promega) followed by MIC_{99} calculations over the concentration range 0–200 μg ml^{-1} (Franzblau *et al.*, 1998).

Determination of the whole-cell effects of NAS analogues on fatty acid and mycolic acid synthesis.

M. bovis BCG cultures were grown to OD_{600} 0.4 in the presence of 0.25 % Tween 80. The NAS analogues were added at various concentrations followed by incubation at 37 °C for 8 h and then 1 μCi (37 kBq) ml^{-1}

[1,2- ^{14}C]acetate (50–62 mCi mmol^{-1} , GE Healthcare, Amersham Bioscience) was added to the cultures, followed by further incubation at 37 °C for 16 h. The ^{14}C -labelled cells were harvested by centrifugation at 2000 *g* followed by washing with PBS. The ^{14}C -labelled control and NAS-treated cells were then subjected to alkaline hydrolysis using 5 % aqueous tetrabutylammonium hydroxide at 100 °C overnight, followed by the addition of 4 ml CH_2Cl_2 , 500 μl CH_3I and 2 ml water, followed by mixing for 30 min. The upper aqueous phase was discarded following centrifugation and the lower organic phase washed three times with water and evaporated to dryness. The resulting fatty acid methyl esters (FAMES) and mycolic acid methyl esters (MAMES) were redissolved in diethyl ether, and the supernatant was again removed after centrifugation and evaporated to dryness and redissolved in 200 μl CH_2Cl_2 . An equivalent aliquot (20 μl) or equal counts (50 000 c.p.m.) of the resulting solution of FAMES and MAMES was subjected to TLC using silica gel plates (5735 silica gel 60F₂₅₄; Merck), developed in petroleum ether/acetone (95:5). Autoradiograms were produced by overnight exposure to Kodak X-Omat AR film to reveal ^{14}C -labelled FAMES and MAMES. Alternatively, free lipids were extracted from the ^{14}C -labelled cells and crude lipids examined by TLC for PGL and phospholipid synthesis using the procedures of Dobson *et al.* (1985).

Preparation of cytosolic fractions, and FAS-I and FAS-II assays.











Cytosolic extracts, enriched for FAS-I and FAS-II using ammonium sulphate precipitation, of *M. smegmatis* mc²155/pVV16 and *M. smegmatis* mc²155/pVV16-Rv0636 (approx. 10 g) were prepared as described previously (Kremer *et al.*, 2002a). The final extract containing the FAS-I and FAS-II activities was dissolved in 5 ml 50 mM MOPS pH 7.9, 5 mM β -mercaptoethanol, 10 mM MgCl_2 . Protein concentrations were determined using the BCA protein assay reagent kit (Pierce). FAS-I and FAS-II assays were conducted as previously described using the 40–80 % ammonium sulfate fraction (Kremer *et al.*, 2002b; Slayden *et al.*, 1996).

RESULTS AND DISCUSSION

Biological evaluation of NAS-21 analogues


NAS-21 has been shown to target the β -hydroxylacyl-ACP dehydratase FabZ of *P. falciparum* (Sharma *et al.*, 2003). The mycobacterial FabZ (Rv0635–637) is a potentially attractive target for such an inhibitor; therefore we sought to synthesize and evaluate NAS-21 analogues against *M. bovis* BCG, which possesses a similar drug profile to *M. tuberculosis* in terms of sensitivity (Larsen *et al.*, 2002; Vilcheze *et al.*, 2005). The results of the whole-cell analysis of NAS-21 analogues against *M. bovis* BCG pVV16 and *M. bovis* BCG/pVV16-Rv0636, which overexpresses Rv0636, are shown in Table 1. It is clearly evident that the

Table 1. Structures of NAS-21 analogues, whole-cell inhibitory activity against *M. bovis* BCG and *in vitro* inhibition of *M. smegmatis* FAS-II activity

Label	Structure	Whole-cell <i>M. bovis</i> BCG activity MIC ₉₉ (µg ml ⁻¹)		<i>In vitro M. smegmatis</i> FAS-II activity IC ₅₀ (µg ml ⁻¹)	
		pVV16	pVV16-Rv0636	pVV16	pVV16-Rv0636
NAS-21		63	105	94	174
1		49	67	69	92
2		54	77	42	85
3		170	241	35	35
4		78	92	28	72
5		>250	>250	19	74
6		>250	>250	55	84
7		>250	>250	100	152
8		>250	>250	98	165
9		>250	>250	117	125

COCH₂COCF₃ group plays a central role in the activity of NAS-21 analogues, because the simple conversion of this group to the COCH₃ functionality resulted in the inactivation of the compounds (MIC₉₉>250 µg ml⁻¹) (data not shown). Two possible explanations for this observed decrease in activity are (i) the di-keto nature of the analogue may mimic the β-keto substrate utilized in


FAS-II and may act as a competitive inhibitor or (ii) the presence of the CF₃ group may stabilize the formation of the keto–enol tautomer of these analogues, which may increase the interaction of the drug with the enzyme's active site. Extension in the *para*-position of the aromatic ring in NAS-21 resulted in analogues with a significant reduction in activity (Table 1). This is demonstrated by the



Scheme 2. Method for production of NAS-91 analogues.

Table 2. Structures of NAS-91 analogues, whole-cell inhibitory activity against *M. bovis* BCG and *in vitro* inhibition of *M. smegmatis* FAS-II activity

Label	Structure	Whole-cell <i>M. bovis</i> BCG activity MIC ₉₉ (µg ml ⁻¹)		<i>In vitro M. smegmatis</i> FAS-II activity IC ₅₀ (µg ml ⁻¹)	
		pVV16	pVV16-Rv0636	pVV16	pVV16-Rv0636
NAS-91		>250	>250	154	185
10		>250	>250	155	165
11		>250	>250	76	176
12		>250	>250	>200	>200
13		43	>250	96	>200
14		50	116	98	>200
15		18	100	98	184
16		78	150	150	185



Scheme 3. Method for adding a linker arm to 5-chloro-8-hydroxyquinolone.

biphenyl group (7–9), thus indicating that modifications extending in this position are not well tolerated. Comparable whole-cell activity of the parent drug NAS-21 and analogues 1, 2 and 4 was demonstrated against *M. bovis* BCG/pVV16. A significant decrease in whole-cell activity against the Rv0636-overexpressing *M. bovis* BCG strain was also observed, suggesting that the product of this gene may represent the cellular target for NAS-21 and analogues 1, 2 and 4.

Effects of NAS-21 analogues on activity of FAS-I and FAS-II in cell-free extracts

To further evaluate the biological properties of NAS-21 analogues and to investigate their potential target, Rv0636, a series of *in vitro* FAS-I and FAS-II assays were performed on crude cell-free extracts of *M. smegmatis* as previously described by Slayden *et al.* (1996). The analysis was performed on extracts isolated from both *M. smegmatis*/pVV16 and *M. smegmatis*/pVV16-Rv0636. The activity of each analogue was measured by the incorporation of radiolabel into extractable lipids. Specific assays were utilized by using priming units in the form of two different fatty acyl-CoAs, either acetyl-CoA or palmitoyl-CoA, for FAS-I or FAS-II, respectively. In both cases [1, 2-¹⁴C]malonyl-CoA was utilized as the radiolabelled carbon donor. In the case of FAS-I, [1,2-¹⁴C]malonyl-CoA coupled with acetyl-CoA to form short-chain fatty acids. However, in the case of FAS-II, [1,2-¹⁴C]malonyl-CoA is transacylated by *mtFabD* to form [1,2-¹⁴C]malonyl-AcpM, which is subsequently used for the initiation of FAS-II by *mtFabH* (Choi *et al.*, 2000). AcpM supplementation in the FAS-II assays drives the reaction towards the production of [1,2-¹⁴C]malonyl-AcpM. Inhibition (IC₅₀) values were determined by varying the concentrations of the drug and by measuring the incorporation of radioactivity into extractable lipids. The results of the crude cell-free extract assay revealed that none of the analogues synthesized inhibited FAS-I (data not shown). Encouragingly, an increased activity was observed for most analogues against FAS-II (Table 1). Analogues 1–6 gave good *in vitro* activity against the cell-free *M. smegmatis* pVV16 extracts of FAS-II. In particular 3, 4 and 5 gave IC₅₀ values of 35, 28 and 19 µg ml⁻¹, respectively, against the *M. smegmatis*/pVV16 FAS-II extract. An increase in resistance was also observed for *M. smegmatis*/pVV16-Rv0636, further suggesting Rv0636 to be a potential target of the analogues. Interestingly, the whole-cell analysis of analogues 3 and 5 gave very poor activities (Table 1), indicating that these

modifications affect the permeability of the drug across the cell wall or that they are modified prior to reaching their target. It was also interesting that analogues 1 and 2, which gave the most pronounced effects against whole cells of *M. bovis* BCG/pVV16 and *M. bovis* BCG/pVV16-Rv0636, did not give the same marked response compared to 4 and 5 in relation to FAS-II inhibition with the same strains (Table 1). Analogues 7–9 were inactive against whole cells; however, moderate activity was observed in FAS-II assays (Table 1), implying that cell permeability may be a contributing factor towards the lack of whole-cell activity of these biphenyl-containing analogues.

Biological evaluation of NAS-91 analogues

NAS-91 showed poor whole-cell activity against both *M. bovis* BCG/pVV16 and *M. bovis* BCG/pVV16-Rv0636 and no inhibition was observed even at high concentrations (>250 µg ml⁻¹) (Table 2). The observed poor inhibition of *M. bovis* BCG growth was surprising since Gratraud *et al.* (2008) recently reported a MIC value of 25 µg ml⁻¹ against *M. bovis* BCG for NAS-91, although the MIC values reported for NAS-21 (50 µg ml⁻¹) by Gratraud *et al.* (2008) are similar to the values (63 µg ml⁻¹) reported in this study. A key feature of note in the studies by Gratraud *et al.* (2008) was that the MIC values were determined on Middlebrook 7H11 agar plates by visualizing plaques following serial dilution. In contrast, in this present study, MIC values for NAS-91 (as well as NAS-21) were determined using the more established and sensitive Alamar Blue method (Franzblau *et al.*, 1998) in Sauton's liquid medium. It is clear that MIC values for NAS-91 in particular are different on liquid and solid media. This is not totally surprising since similar observations have been reported for drug inhibition of mycobacterial strains. For instance, *M. smegmatis* is sensitive to econazole and clotrimazole on LB solid agar plates, with MIC values of 2 and 0.5 µg ml⁻¹, respectively (Burguiere *et al.*, 2005). However, when *M. smegmatis* is cultured in Sauton's liquid medium, the MIC values are higher than those determined on agar plates, with econazole at 20 µg ml⁻¹ (10-fold higher) and clotrimazole at 15 µg ml⁻¹ (30-fold higher), respectively. Interestingly, it is clear that a concentration of 100 µg ml⁻¹ of NAS-91 in liquid media is only partially inhibiting mycolate synthesis (50%) in the Gratraud *et al.* (2008) study, which is at four times the MIC value on solid media. This is further evidence for the MIC value for NAS-91 being different on solid and liquid media.

Analogues **13–16** demonstrated significantly improved whole-cell activity in comparison to NAS-91. The simple introduction of a methyl modification in analogue **15** resulted in the most improved whole-cell activity, with an MIC₉₉ value of 18 µg ml⁻¹ against *M. bovis* BCG/pVV16. Encouragingly, resistance was shown against analogue **15** when *M. bovis* BCG/pVV16-Rv0636 was used, with an increase in MIC₉₉ to 100 µg ml⁻¹. Structurally, analogues **13** and **14** indicate that there is more scope to extend the modification in the *ortho*-position by two or more carbons. Analogues **10** and **11** were primarily developed to assess the feasibility of introducing a linker arm into the analogues whilst changing the functionalities on the aromatic ring. As indicated in Table 2, the low biological activity of these analogues was comparable to that of NAS-91. Initially it was felt that the linker arm might have compromised activity by reorientating the analogue within the active site, thus affecting its interactions with the target. However, as observed with analogues **13–16**, modifications in the *ortho*-position of the aromatic ring greatly increase the potency of this analogue, suggesting it is the nature of the modification on **10** and **11** which has compromised their whole-cell activity. From the activities observed with analogues **13–16** it is evident that the hydroxyl group of

the secondary aromatic functionality does not play an important part in the protein–drug interaction, as activity was still observed in these analogues. Finally, the introduction of a second aromatic group in the *para*-position (**12**) compromised the whole-cell activity against both *M. bovis* BCG/pVV16 and *M. bovis* BCG/pVV16-Rv0636. This initial study suggests that there is limited scope to further extend in the *para*-position with a second aromatic ring; however, this requires verification by formulating a more comprehensive library.

Effects of NAS-91 analogues on activity of FAS-I and FAS-II in cell-free extracts

To further evaluate the activities of the NAS-91 analogues, a series of *in vitro* FAS-I and FAS-II assays were performed on crude cell-free extracts of *M. smegmatis*. As with the NAS-21 analogues, the crude *M. smegmatis* cell-free FAS-I assays revealed that none of the analogues inhibited FAS-I (data not shown). Analogues **10** and **12** demonstrated similar effects to NAS-91 against FAS-II activity in *M. smegmatis* cell-free extracts (Table 2). Encouragingly, analogues **11** and **13–15** gave a marked increase in *in vitro* activity against FAS-II, and extracts from *M. smegmatis*




Fig. 2. TLC-autoradiography of *M. bovis* BCG FAMES and MAMES after NAS-21 and NAS-91 analogue treatment. (A) NAS-21 analogue **1** (0–100 µg ml⁻¹) and (B) NAS-91 analogue **15** (0–100 µg ml⁻¹) were titrated into the *M. bovis* BCG/pVV16 cultures at an OD₆₀₀ of 0.4 prior to labelling with 1 µCi (37 kBq) [1,2-¹⁴C]acetate ml⁻¹ for 8 h. [¹⁴C]FAMES and [¹⁴C]MAMES were extracted and resolved by TLC. An equivalent aliquot (20 µl) of the resulting solution of FAMES and MAMES was subjected to TLC using silica gel plates (5735 silica gel 60F₂₅₄; Merck), developed in petroleum ether/acetone (95:5, v/v). Autoradiograms were produced by overnight exposure to Kodak X-Omat AR film to reveal ¹⁴C-labelled FAMES and MAMES.

pVV16-Rv0636 FAS-II extract showed resistance to these analogues. Analogues 13–15 also showed good whole-cell activity against whole-cell *M. bovis* BCG/pVV16, providing further evidence that these analogues would form a good basis to generate a secondary library of NAS-91 analogues.

Effects of NAS-21 and NAS-91 analogues on FAME and MAME synthesis

M. bovis BCG/pVV16 was grown in the presence of the NAS analogues at various concentrations, followed by [1,2-¹⁴C]acetate labelling and analysis by TLC separation of FAMES and MAMES. An example of the results, for analogues 1 and 15, is shown in Fig. 2. There was a decrease in the incorporation of radioactivity into FAMES and MAMES in the presence of NAS-21, analogues 1 and 15. Since analogues 1 and 15 were shown not to inhibit FAS-I (data not shown), the experiment was repeated; equal counts were loaded and the TLC profiles of FAMES and MAMES reanalysed (Fig. 3A, D). It is clear from this analysis that analogues 1 and 15 only inhibit the synthesis of α - and keto-MAMES and not that of FAMES (Fig. 3), consistent with the earlier *in vitro* data (Tables 1 and 2). As an additional control the synthesis of cell envelope lipids was also examined (Fig. 3). Analogues 1 and 15 again do not inhibit general fatty acid synthesis as the synthesis of PGL (Fig. 3B, E) and phospholipids (Fig. 3C, F) remains

unaffected. Resistance was also observed upon the over-expression of pVV16-Rv0636, supporting the earlier MIC₉₉ and *in vitro* studies and thereby strengthening the evidence that these analogues target Rv0636 (Fig. 2). Similar results were observed with the other active analogues (2, 4, 13, 14 and 16).

Concluding remarks

In conclusion, no activity was observed against FAS-I for either NAS-21 or NAS-91. In general, all the analogues showed *in vitro* activity against FAS-II extracts, and the Rv0636-overexpressing strain carrying pVV16-Rv0636 showed a marked increase in resistance. Whole-cell FAME and MAME analysis for most analogues demonstrated a decrease in both mycolic acid and fatty acid biosynthesis. Interestingly, this effect of the analogues was also reduced in *M. bovis* BCG/pVV16-Rv0636, thus further implicating Rv0636 as the target for these FabZ dehydratase inhibitors. The present study extends the initial findings of Gratraud *et al.* (2008), who did not perform FAS-I and FAS-II *in vitro* enzyme studies, using NAS-21 and NAS-91 to examine mycolate inhibition directly. Although the study of Gratraud *et al.* (2008) demonstrated that NAS-21 and NAS-91 also inhibited oleate biosynthesis it is clear that this represents a secondary target since it is non-essential, in contrast to Rv0636, which has been shown to




Fig. 3. TLC-autoradiography of *M. bovis* BCG lipids after NAS-21 and NAS-91 analogue treatment. (A, D) Analysis of FAMES and MAMES following treatment with NAS-21 analogue 1 (20 $\mu\text{g ml}^{-1}$) and NAS-91 analogue 15 (15 $\mu\text{g ml}^{-1}$) and resolved by TLC using equal counts (50 000 c.p.m.) as described in Methods. Lipid extractions were performed as described by Dobson *et al.* (1985) and a 50 000 c.p.m. aliquot analysed using silica gel plates (5735 silica gel 60F₂₅₄; Merck). (B, E) Phenolic glycolipids (PGL) were identified by 2D TLC [direction 1, chloroform/methanol (94:4, v/v); direction 2, toluene/acetone (80:20, v/v)]. (C, F) Phospholipids (P), phosphatidylinositol (PI), acyl-phosphatidylinositol dimannoside (Ac₁PIM₂) and diacyl-phosphatidylinositol dimannoside (Ac₂PIM₂) were identified by 2D TLC [direction 1, chloroform/methanol/water (60:30:6, by vol.); direction 2, chloroform/acetic acid/methanol/water (40:25:3:6, by vol.)]. Autoradiograms were produced by overnight exposure to Kodak X-Omat AR film to reveal ¹⁴C-labelled FAMES, MAMES and lipids.

be essential (Brown *et al.*, 2007a). In comparison to the FAS-II flavonoid inhibitors (Brown *et al.*, 2007b), our NAS-21 and NAS-91 analogues demonstrated a marked enhancement in activity; in some cases an eightfold increase is observed. Therefore NAS-21 and NAS-91 analogues represent good candidates for further development of drugs targeting the mycobacterial FAS-II dehydratase. However, to fully establish the potential therapeutic properties of NAS-21 and NAS-91, their *in vitro* activity against the heterodimers Rv0635-Rv0636 (HadAB) and Rv0636-Rv0637 (HadBC) must be also evaluated. The recent development of an *in vitro* assay for the FAS-II dehydratase activity (Sacco *et al.*, 2007) will help us to better understand the inhibitory activity of these compounds.

ACKNOWLEDGEMENTS

G. S. B. acknowledges support in the form of a Royal Society Wolfson Research Merit Award and a Personal Research Chair from Mr James Bardrick, as a former Lister Institute-Jenner Research Fellow, the Medical Research Council (UK), and the Wellcome Trust.

REFERENCES

- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G. & Jacobs, W. R., Jr (1994). *inhA*, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*. *Science* **263**, 227–230.
- Banerjee, A., Sugantino, M., Sacchetti, J. C. & Jacobs, W. R., Jr (1998). The *mabA* gene from the *inhA* operon of *Mycobacterium tuberculosis* encodes a β -ketoacyl reductase that fails to confer isoniazid resistance. *Microbiology* **144**, 2697–2704.
- Brown, A. K., Sridharan, S., Kremer, L., Lindenberg, S., Dover, L. G., Sacchetti, J. C. & Besra, G. S. (2005). Probing the mechanism of the *Mycobacterium tuberculosis* β -ketoacyl-acyl carrier protein synthase III *mtFabH*: factors influencing catalysis and substrate specificity. *J Biol Chem* **280**, 32539–32547.
- Brown, A. K., Bhatt, A., Singh, A., Saparia, E., Evans, A. F. & Besra, G. S. (2007a). Identification of the dehydratase component of the mycobacterial mycolic acid-synthesizing fatty acid synthase-II complex. *Microbiology* **153**, 4166–4173.
- Brown, A. K., Papaemmanouil, A., Bhowruth, V., Bhatt, A., Dover, L. G. & Besra, G. S. (2007b). Flavonoid inhibitors as novel antimycobacterial agents targeting Rv0636, a putative dehydratase enzyme involved in *Mycobacterium tuberculosis* fatty acid synthase II. *Microbiology* **153**, 3314–3322.
- Burguiere, A., Hitchen, P. G., Dover, L. G., Dell, A. & Besra, G. S. (2005). Altered expression profile of mycobacterial surface glycopeptidolipids following treatment with the antifungal azole inhibitors econazole and clotrimazole. *Microbiology* **151**, 2087–2095.
- CDC (2006). Emergence of *Mycobacterium tuberculosis* with extensive resistance to second-line drugs – worldwide, 2000–2004. *MMWR Morb Mortal Wkly Rep* **55**, 301–305.
- Choi, K. H., Kremer, L., Besra, G. S. & Rock, C. O. (2000). Identification and substrate specificity of β -ketoacyl (acyl carrier protein) synthase III (*mtFabH*) from *Mycobacterium tuberculosis*. *J Biol Chem* **275**, 28201–28207.
- Dobson, G., Minnikin, D. E., Minnikin, S. M., Parlett, J. H., Goodfellow, M., Ridell, M. & Magnusson, M. (1985). Systematic analysis of complex mycobacterial lipids. In *Chemical Methods in Bacterial Systematics*, pp. 237–265. Edited by M. Goodfellow & D. E. Minnikin. London: Academic Press.
- Franzblau, S. G., Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez, A., Degnan, M. T., Cook, M. B., Quenzer, V. K. & other authors (1998). Rapid, low-technology MIC determination with clinical *Mycobacterium tuberculosis* isolates by using the microplate Alamar Blue assay. *J Clin Microbiol* **36**, 362–366.
- Gande, R., Gibson, K. J., Brown, A. K., Krumbach, K., Dover, L. G., Sahn, H., Shioyama, S., Oikawa, T., Besra, G. S. & Eggeling, L. (2004). Acyl-CoA carboxylases (*accD2* and *accD3*), together with a unique polyketide synthase (*Cg-pks*), are key to mycolic acid biosynthesis in Corynebacteriaceae such as *Corynebacterium glutamicum* and *Mycobacterium tuberculosis*. *J Biol Chem* **279**, 44847–44857.
- Gratraud, P., Surolia, N., Besra, G., Surolia, A. & Kremer, L. (2008). Antimycobacterial activity and mechanism of action of NAS-91. *Antimicrob Agents Chemother* **52**, 1162–1166.
- Kass, L. R. & Bloch, K. (1967). On the enzymatic synthesis of unsaturated fatty acids in *Escherichia coli*. *Proc Natl Acad Sci U S A* **58**, 1168–1173.
- Kass, L. R., Brock, D. J. & Bloch, K. (1967). β -hydroxydecanoyl thioester dehydrase. I. Purification and properties. *J Biol Chem* **242**, 4418–4431.
- Kaye, K. & Frieden, T. R. (1996). Tuberculosis control: the relevance of classic principles in an era of acquired immunodeficiency syndrome and multidrug resistance. *Epidemiol Rev* **18**, 52–63.
- Kikuchi, S. & Kusaka, T. (1984). Purification of NADPH-dependent enoyl-CoA reductase involved in the malonyl-CoA dependent fatty acid elongation system of *Mycobacterium smegmatis*. *J Biochem* **96**, 841–848.
- Kremer, L., Baulard, A., Estaquier, J., Content, J., Capron, A. & Locht, C. (1995). Analysis of the *Mycobacterium tuberculosis* 85A antigen promoter region. *J Bacteriol* **177**, 642–653.
- Kremer, L., Douglas, J. D., Baulard, A. R., Morehouse, C., Guy, M. R., Alland, D., Dover, L. G., Lakey, J. H., Jacobs, W. R., Jr & other authors (2000). Thiolactomycin and related analogues as novel antimycobacterial agents targeting KasA and KasB condensing enzymes in *Mycobacterium tuberculosis*. *J Biol Chem* **275**, 16857–16864.
- Kremer, L., Dover, L. G., Carrere, S., Nampoothiri, K. M., Lesjean, S., Brown, A. K., Brennan, P. J., Minnikin, D. E., Locht, C. & Besra, G. S. (2002a). Mycolic acid biosynthesis and enzymic characterization of the β -ketoacyl-ACP synthase A-condensing enzyme from *Mycobacterium tuberculosis*. *Biochem J* **364**, 423–430.
- Kremer, L., Dover, L. G., Carrere, S., Nampoothiri, K. M., Lesjean, S., Brown, A. K., Brennan, P. J., Minnikin, D. E., Locht, C. & Besra, G. S. (2002b). Mycolic acid biosynthesis and enzymic characterization of the β -ketoacyl-ACP synthase A-condensing enzyme from *Mycobacterium tuberculosis*. *Biochem J* **364**, 423–430.
- Larsen, M. H., Vilcheze, C., Kremer, L., Besra, G. S., Parsons, L., Salfinger, M., Heifets, L., Hazbon, M. H., Alland, D. & other authors (2002). Overexpression of *inhA*, but not *kasA*, confers resistance to isoniazid and ethionamide in *Mycobacterium smegmatis*, *M. bovis* BCG and *M. tuberculosis*. *Mol Microbiol* **46**, 453–466.
- Lea-Smith, D. J., Pyke, J. S., Tull, D., McConville, M. J., Coppel, R. L. & Crellin, P. K. (2007). The reductase that catalyzes mycolic motif synthesis is required for efficient attachment of mycolic acids to arabinogalactan. *J Biol Chem* **282**, 11000–11008.
- Leesong, M., Henderson, B. S., Gillig, J. R., Schwab, J. M. & Smith, J. L. (1996). Structure of a dehydratase-isomerase from the bacterial pathway for biosynthesis of unsaturated fatty acids: two catalytic activities in one active site. *Structure* **4**, 253–264.

- Mdluli, K., Slayden, R. A., Zhu, Y., Ramaswamy, S., Pan, X., Mead, D., Crane, D. D., Musser, J. M. & Barry, C. E., III (1998). Inhibition of a *Mycobacterium tuberculosis* β -ketoacyl ACP synthase by isoniazid. *Science* **280**, 1607–1610.
- Portevin, D., de Sousa-D'Auria, C., Montrozier, H., Houssin, C., Stella, A., Laneelle, M. A., Bardou, F., Guilhot, C. & Daffe, M. (2005). The acyl-AMP ligase FadD32 and AccD4-containing acyl-CoA carboxylase are required for the synthesis of mycolic acids and essential for mycobacterial growth: identification of the carboxylation product and determination of the acyl-CoA carboxylase components. *J Biol Chem* **280**, 8862–8874.
- Sacco, E., Covarrubias, A. S., O'Hare, H. M., Carroll, P., Eynard, N., Jones, T. A., Parish, T., Daffe, M., Backbro, K. & Quemard, A. (2007). The missing piece of the type II fatty acid synthase system from *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* **104**, 14628–14633.
- Schaeffer, M. L., Agnihotri, G., Volker, C., Kallender, H., Brennan, P. J. & Lonsdale, J. T. (2001). Purification and biochemical characterization of the *Mycobacterium tuberculosis* β -ketoacyl-acyl carrier protein synthases KasA and KasB. *J Biol Chem* **276**, 47029–47037.
- Sharma, S. K., Kapoor, M., Ramya, T. N., Kumar, S., Kumar, G., Modak, R., Sharma, S., Surolia, N. & Surolia, A. (2003). Identification, characterization, and inhibition of *Plasmodium falciparum* β -hydroxyacyl-acyl carrier protein dehydratase (FabZ). *J Biol Chem* **278**, 45661–45671.
- Slayden, R. A., Lee, R. E., Armour, J. W., Cooper, A. M., Orme, I. M., Brennan, P. J. & Besra, G. S. (1996). Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. *Antimicrob Agents Chemother* **40**, 2813–2819.
- Takayama, K., Wang, C. & Besra, G. S. (2005). Pathway to synthesis and processing of mycolic acids in *Mycobacterium tuberculosis*. *Clin Microbiol Rev* **18**, 81–101.
- Ullmann, F. & Sponagel, P. (1905). Concerning the phenylisation of phenolene. *Ber Dtsch Chem Ges* **38**, 2211–2212.
- Vilcheze, C., Weisbrod, T. R., Chen, B., Kremer, L., Hazbon, M. H., Wang, F., Alland, D., Sacchetti, J. C. & Jacobs, W. R., Jr (2005). Altered NADH/NAD⁺ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. *Antimicrob Agents Chemother* **49**, 708–720.
- Waller, R. F., Ralph, S. A., Reed, M. B., Su, V., Douglas, J. D., Minnikin, D. E., Cowman, A. F., Besra, G. S. & McFadden, G. I. (2003). A type II pathway for fatty acid biosynthesis presents drug targets in *Plasmodium falciparum*. *Antimicrob Agents Chemother* **47**, 297–301.

Edited by: W. Bitter